ClinicalTrials.gg
CompletedNCT00856193Updated Sep 14, 2016Results posted

A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of Placebo and NVA237 in Chronic Obstructive Pulmonary Disease, sponsored by Novartis. Completed at 2 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-09-14.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
61st of 73
33 · median 152
Started
2009
with 3 others
Phase 2
19 of 73
none open now
Registered
6th of 73
by date
Lead sponsor
6 of 73
Novartis

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 61st largest by enrollment, is one of 4 that started in 2009, is one of 19 in phase 2, and was the 6th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study was intended to assess how well inhaled NVA237 opens up the airways of patients with mild, moderate or severe COPD over a 24 hour period after a 14 day treatment period.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
  • Bronchodilator
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged greater than 40 years with Current or ex-smokers

Exclusion criteria

Exclusion Criteria:

  • Cardiac (heart) disorders, history of asthma, requiring oxygen therapy. Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
33 participants (actual)

Study arms

  • Placebo comparator
    Placebo then NVA237 50μg

    Placebo 50 μg capsules followed by NVA237 50 μg capsules for inhalation once daily with Concept 1 device.

    Drug: Placebo · Drug: NVA237

  • Experimental
    NVA237 50μg then placebo

    NVA237 50 μg capsules followed by matching placebo 50 μg capsules for inhalation once daily with Concept 1 device.

    Drug: Placebo · Drug: NVA237

Interventions

  • DrugPlacebo

    Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.

  • DrugNVA237

    NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.

06

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-24 Hours on Day 14

    Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. This outcome measures the change is FEV1 from predose (day 1) to the readings taken 0-24 hours post dose on day 14. The variable was analyzed with an analysis-of-covariance model which included baseline FEV1 value as a covariate.

    Time frame: From Day 1 to 0-24 hours after drug administration on Day 14

Secondary outcomes

  1. Forced Expiratory Volume in One Second (FEV1) AUC 0-12 Hours on Day 14

    Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. This outcome measures the change is FEV1 from pre-dose (day 1) to the readings taken 0-12 hours post dose on day 14. The variable was analyzed with an analysis-of-covariance model which included baseline FEV1 value as a covariate.

    Time frame: From day 1 to 0 -12 hours after drug administration on Day 14

  2. Forced Expiratory Volume in One Second (FEV1) AUC 12-24 Hours on Day 14

    Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. This outcome measures the change is FEV1 from pre-dose (day 1) to the readings taken 12-24 hours post dose on day 14. The variable was analyzed with an analysis-of-covariance model which included baseline FEV1 value as a covariate.

    Time frame: From Day 1 to 12 hours-24 hours after drug administration on Day 14

  3. Number of Participants Who Experienced Adverse Events (AEs), Serious Adverse Events (SAEs)

    According to FDA 21CFR 314.80, a serious adverse event (SAE) is described as any adverse event that leads to death, is life threatening , causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above. See Adverse Events module for details.

    Time frame: Day 14

07

Results

Posted May 6, 2011

Participant flow

Period 1
Participant flow — Period 1
MilestoneNVA237 50μg Then PlaceboPlacebo Then NVA237 50μg
Started1617
Completed1617
Not completed00
Period 2
Participant flow — Period 2
MilestoneNVA237 50μg Then PlaceboPlacebo Then NVA237 50μg
Started1617
Completed1615
Not completed02
Withdrew: Abnormal test procedure results01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryForced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-24 Hours on Day 14

Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. This outcome measures the change is FEV1 from predose (day 1) to the readings taken 0-24 hours post dose on day 14. The variable was analyzed with an analysis-of-covariance model which included baseline FEV1 value as a covariate.

Time frame:
From Day 1 to 0-24 hours after drug administration on Day 14
Reported as:
Least squares mean · Liters
Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-24 Hours on Day 14
LitersNVA237 50μgPlacebo
Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-24 Hours on Day 141.827 ± 0.03301.664 ± 0.0324
SecondaryForced Expiratory Volume in One Second (FEV1) AUC 0-12 Hours on Day 14

Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. This outcome measures the change is FEV1 from pre-dose (day 1) to the readings taken 0-12 hours post dose on day 14. The variable was analyzed with an analysis-of-covariance model which included baseline FEV1 value as a covariate.

Time frame:
From day 1 to 0 -12 hours after drug administration on Day 14
Reported as:
Least squares mean · Liters
Forced Expiratory Volume in One Second (FEV1) AUC 0-12 Hours on Day 14
LitersNVA237 50μgPlacebo
Forced Expiratory Volume in One Second (FEV1) AUC 0-12 Hours on Day 141.879 ± 0.03461.714 ± 0.0340
SecondaryForced Expiratory Volume in One Second (FEV1) AUC 12-24 Hours on Day 14

Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. This outcome measures the change is FEV1 from pre-dose (day 1) to the readings taken 12-24 hours post dose on day 14. The variable was analyzed with an analysis-of-covariance model which included baseline FEV1 value as a covariate.

Time frame:
From Day 1 to 12 hours-24 hours after drug administration on Day 14
Reported as:
Least squares mean · Liters
Forced Expiratory Volume in One Second (FEV1) AUC 12-24 Hours on Day 14
LitersNVA237 50μgPlacebo
Forced Expiratory Volume in One Second (FEV1) AUC 12-24 Hours on Day 141.776 ± 0.03441.615 ± 0.0339
SecondaryNumber of Participants Who Experienced Adverse Events (AEs), Serious Adverse Events (SAEs)

According to FDA 21CFR 314.80, a serious adverse event (SAE) is described as any adverse event that leads to death, is life threatening , causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above. See Adverse Events module for details.

Time frame:
Day 14
Reported as:
Number · Participants
Number of Participants Who Experienced Adverse Events (AEs), Serious Adverse Events (SAEs)
ParticipantsNVA237 50μgPlacebo
Overall Adverse Events24
Serious Adverse Events (SAEs)00

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/33 (0%)2/33 (6.1%)
NVA237 50 μg—0/31 (0%)0/31 (0%)
Most frequent other events
Most frequent other events
EventPlaceboNVA237 50 μg
Gastrointestinal disordersGastrointestinal disorders2/330/31

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Randomized Patients
Mean60.5 ± 9.13
Sex: Female, Male
Sex: Female, Male(Participants)All Randomized Patients
Female11
Male22
08

Study locations

2 sites
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • Harrison Clinical Research Deutschland GmbH
    Albrechtstrasse 14, Munich 80636, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2009
First posted
Mar 5, 2009
Start
Feb 2009
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
May 6, 2011
Last update
Sep 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00856193
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Mar 5, 2009
Start date
Feb 2009
Primary completion
May 2009
Completion
May 2009
Results posted
May 6, 2011
Last update
Sep 14, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion